Teriflunomide inhibits rapidly dividing cells, including activated T cells, which are thought to drive the disease process in MS. Teriflunomide may decrease the risk of infections compared to chemotherapy-like drugs because of its more-limited effects on the immune system.<ref>{{cite journal

 
See '''[[leflunomide]]''' for information on pharmacokinetics, side effects, contraindications and other data.
